2018 - Fellow of the Royal Society, United Kingdom
His primary areas of investigation include Cancer, Genetic heterogeneity, Cancer research, Genetics and Chromosome instability. His work on Breast cancer and Tumor microenvironment as part of general Cancer study is frequently linked to Context, bridging the gap between disciplines. His Genetic heterogeneity research is multidisciplinary, relying on both Bioinformatics, Genomics, Somatic evolution in cancer, Computational biology and Drug resistance.
Charles Swanton interconnects Renal cell carcinoma, Clear cell, Downregulation and upregulation, Cell cycle and Cyclin-dependent kinase 6 in the investigation of issues within Cancer research. His study in Chromosome instability is interdisciplinary in nature, drawing from both Aneuploidy and Immunology. His Immunology research incorporates elements of Internal medicine, Lung cancer, Oncology and Metastasis.
Charles Swanton mainly focuses on Cancer research, Cancer, Internal medicine, Oncology and Bioinformatics. In his study, Carcinoma and Immunotherapy is strongly linked to Lung cancer, which falls under the umbrella field of Cancer research. The Cancer study combines topics in areas such as Genetic heterogeneity and Chromosome instability.
His Genetic heterogeneity study deals with Somatic evolution in cancer intersecting with Evolutionary biology. His Oncology study combines topics in areas such as Clinical trial, Pathology, Trastuzumab, Immunology and Biomarker. His Bioinformatics study combines topics from a wide range of disciplines, such as Tumour heterogeneity, Disease and Drug resistance.
Charles Swanton spends much of his time researching Cancer research, Cancer, Internal medicine, Lung cancer and Oncology. His research integrates issues of Cancer cell and CD8, Immune system, Antigen in his study of Cancer research. His study on Breast cancer is often connected to Pandemic as part of broader study in Cancer.
His study in Internal medicine focuses on Cohort in particular. In Lung cancer, Charles Swanton works on issues like KRAS, which are connected to Oncogene and Mutant. Charles Swanton works mostly in the field of Oncology, limiting it down to topics relating to MEDLINE and, in certain cases, Carcinoma, as a part of the same area of interest.
His primary scientific interests are in Cancer research, Pandemic, Severe acute respiratory syndrome coronavirus 2, Cancer and Health care. His biological study spans a wide range of topics, including T cell and Human leukocyte antigen, CD8, Antigen, Immunogenicity. Charles Swanton does research in Cancer, focusing on Breast cancer specifically.
The various areas that Charles Swanton examines in his Breast cancer study include Tumor-infiltrating lymphocytes, Stromal tumor and Predictive biomarker. His Health care research integrates issues from Infectious disease transmission and Medical emergency. While the research belongs to areas of Lung cancer, Charles Swanton spends his time largely on the problem of Precision medicine, intersecting his research to questions surrounding Carcinoma and Oncology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Guidelines for the use and interpretation of assays for monitoring autophagy
Daniel J. Klionsky;Fabio C. Abdalla;Hagai Abeliovich;Robert T. Abraham.
Autophagy (2012)
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)
Daniel J. Klionsky;Kotb Abdelmohsen;Akihisa Abe;Joynal Abedin.
Autophagy (2016)
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.
Marco Gerlinger;Andrew J. Rowan;Stuart Horswell;James Larkin.
The New England Journal of Medicine (2012)
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Nicholas McGranahan;Nicholas McGranahan;Andrew J. S. Furness;Rachel Rosenthal;Sofie Ramskov.
Science (2016)
The causes and consequences of genetic heterogeneity in cancer evolution.
Rebecca A. Burrell;Nicholas McGranahan;Nicholas McGranahan;Jiri Bartek;Charles Swanton.
Nature (2013)
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future.
Nicholas McGranahan;Charles Swanton;Charles Swanton.
Cell (2017)
Tracking the Evolution of Non–Small-Cell Lung Cancer
Mariam Jamal-Hanjani;Gareth A. Wilson;Nicholas McGranahan;Nicolai Juul Birkbak.
The New England Journal of Medicine (2017)
Renal cell carcinoma.
James J. Hsieh;Mark P. Purdue;Sabina Signoretti;Charles Swanton.
Nature Reviews Disease Primers (2017)
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
T.A. Chan;M. Yarchoan;E. Jaffee;C. Swanton.
Annals of Oncology (2019)
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
Christopher Abbosh;Nicolai J. Birkbak;Nicolai J. Birkbak;Gareth A. Wilson;Gareth A. Wilson;Mariam Jamal-Hanjani.
Nature (2017)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
Boston Children's Hospital
Royal Marsden NHS Foundation Trust
University College London
The Francis Crick Institute
University College London
The Francis Crick Institute
The Francis Crick Institute
University of Manchester
Royal Marsden NHS Foundation Trust
University of Edinburgh
Facebook (United States)
University of Naples Federico II
University of Hong Kong
Bangor University
National Research Council Canada
Okayama University
University of Potsdam
University of Reading
Michigan State University
University of Amsterdam
Cornell University
University of Utah
The University of Texas MD Anderson Cancer Center
University of Padua
University of California, San Diego
Leiden University